AAAAAA

   
Results: 1-16 |
Results: 16
ALENDRONATE FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS
Authors: SAAG KG EMKEY R SCHNITZER TJ BROWN JP HAWKINS F GOEMAERE S THAMSBORG G LIBERMAN UA DELMAS PD MALICE MP CZACHUR M DAIFOTIS AG
Citation: Kg. Saag et al., ALENDRONATE FOR THE PREVENTION AND TREATMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS, The New England journal of medicine, 339(5), 1998, pp. 292-299
DYNAMICS OF INSULIN SIGNALING IN 3T3-L1 ADIPOCYTES - DIFFERENTIAL COMPARTMENTALIZATION AND TRAFFICKING OF INSULIN-RECEPTOR SUBSTRATE (IRS)-1 AND IRS-2
Authors: INOUE G CHEATHAM B EMKEY R KAHN CR
Citation: G. Inoue et al., DYNAMICS OF INSULIN SIGNALING IN 3T3-L1 ADIPOCYTES - DIFFERENTIAL COMPARTMENTALIZATION AND TRAFFICKING OF INSULIN-RECEPTOR SUBSTRATE (IRS)-1 AND IRS-2, The Journal of biological chemistry, 273(19), 1998, pp. 11548-11555
5-YEAR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH ORAL ALENDRONATE - EFFECTS ON BONE MASS AND TURNOVER AND SAFETY
Authors: FAVUS M EMKEY R LEITE M DEVOGELAER JP RODRIGUEZ J PEVERLY C KAUR A SANTORA A
Citation: M. Favus et al., 5-YEAR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH ORAL ALENDRONATE - EFFECTS ON BONE MASS AND TURNOVER AND SAFETY, Journal of bone and mineral research, 12, 1997, pp. 189-189
CLINICAL UTILITY OF SKELETAL ALKALINE-PHOSPHATASE (SALP) (TANDEM(R)-ROSTASE(R)) IN MONITORING INDIVIDUAL POSTMENOPAUSAL OSTEOPOROTIC WOMENUNDERGOING ALENDRONATE (ALN) THERAPY
Authors: MIZRAHI L ARMOUR K EMKEY R MARCUS R SANTORA A KRESS B
Citation: L. Mizrahi et al., CLINICAL UTILITY OF SKELETAL ALKALINE-PHOSPHATASE (SALP) (TANDEM(R)-ROSTASE(R)) IN MONITORING INDIVIDUAL POSTMENOPAUSAL OSTEOPOROTIC WOMENUNDERGOING ALENDRONATE (ALN) THERAPY, Journal of bone and mineral research, 12, 1997, pp. 460-460
CROSS-TALK BETWEEN PHORBOL ESTER-MEDIATED SIGNALING AND TYROSINE KINASE PROTOONCOGENES I - ACTIVATION OF PROTEIN-KINASE-C STIMULATES TYROSINE PHOSPHORYLATION AND ACTIVATION OF ERBB2 AND ERBB3
Authors: EMKEY R KAHN CR
Citation: R. Emkey et Cr. Kahn, CROSS-TALK BETWEEN PHORBOL ESTER-MEDIATED SIGNALING AND TYROSINE KINASE PROTOONCOGENES I - ACTIVATION OF PROTEIN-KINASE-C STIMULATES TYROSINE PHOSPHORYLATION AND ACTIVATION OF ERBB2 AND ERBB3, The Journal of biological chemistry, 272(49), 1997, pp. 31172-31181
CROSS-TALK BETWEEN PHORBOL ESTER-MEDIATED SIGNALING AND TYROSINE KINASE PROTOONCOGENES II COMPARISON OF PHORBOL ESTER AND SPHINGOMYELINASE-INDUCED PHOSPHORYLATION OF ERBB2 AND ERBB3
Authors: EMKEY R KAHN CR
Citation: R. Emkey et Cr. Kahn, CROSS-TALK BETWEEN PHORBOL ESTER-MEDIATED SIGNALING AND TYROSINE KINASE PROTOONCOGENES II COMPARISON OF PHORBOL ESTER AND SPHINGOMYELINASE-INDUCED PHOSPHORYLATION OF ERBB2 AND ERBB3, The Journal of biological chemistry, 272(49), 1997, pp. 31182-31189
BONE-MINERAL DENSITY RESPONSE 60 UNOPPOSED ESTERIFIED ESTROGENS - GROUP BMD CHANGES VS INDIVIDUAL-RESPONSES
Authors: MORTOLA J EMKEY R SILFEN S NOLAN JC BRENNAN J
Citation: J. Mortola et al., BONE-MINERAL DENSITY RESPONSE 60 UNOPPOSED ESTERIFIED ESTROGENS - GROUP BMD CHANGES VS INDIVIDUAL-RESPONSES, Fertility and sterility, 1997, pp. 282-282
THE EFFECTS OF ORAL ALENDRONATE ON BONE MASS AND TURNOVER AND SAFETY - 5-YEAR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
Authors: EMKEY R MCILWAIN H FAVUS M LEITE M DEVOGELAER JP RODRIGUEZ J PEVERLY C ARNOLD A KAUR A SANTORA A
Citation: R. Emkey et al., THE EFFECTS OF ORAL ALENDRONATE ON BONE MASS AND TURNOVER AND SAFETY - 5-YEAR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN, Arthritis and rheumatism, 40(9), 1997, pp. 626-626
ALENDRONATE FOR THE MANAGEMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS- RESULTS OF THE MULTICENTER US STUDY
Authors: SAAG K EMKEY R GRUBER B TESSER J LANE N YANOVER M DUBOIS C FREEDHOLM D CAROFANO W DAIFOTIS A
Citation: K. Saag et al., ALENDRONATE FOR THE MANAGEMENT OF GLUCOCORTICOID-INDUCED OSTEOPOROSIS- RESULTS OF THE MULTICENTER US STUDY, Arthritis and rheumatism, 40(9), 1997, pp. 630-630
LOW-DOSE ESTERIFIED ESTROGEN THERAPY - EFFECTS ON BONE, PLASMA ESTRADIOL CONCENTRATIONS, ENDOMETRIUM, AND LIPID-LEVELS
Authors: GENANT HK LUCAS J WEISS S AKIN M EMKEY R MCNANEYFLINT H DOWNS R MORTOLA J WATTS N YANG HM BANAV N BRENNAN JJ NOLAN JC
Citation: Hk. Genant et al., LOW-DOSE ESTERIFIED ESTROGEN THERAPY - EFFECTS ON BONE, PLASMA ESTRADIOL CONCENTRATIONS, ENDOMETRIUM, AND LIPID-LEVELS, Archives of internal medicine, 157(22), 1997, pp. 2609-2615
RAL-GTPASES MEDIATE A DISTINCT DOWNSTREAM SIGNALING PATHWAY FROM RAS THAT FACILITATES CELLULAR-TRANSFORMATION
Authors: URANO T EMKEY R FEIG LA
Citation: T. Urano et al., RAL-GTPASES MEDIATE A DISTINCT DOWNSTREAM SIGNALING PATHWAY FROM RAS THAT FACILITATES CELLULAR-TRANSFORMATION, EMBO journal, 15(4), 1996, pp. 810-816
CLINICAL UTILITY OF BONE SPECIFIC ALKALINE-PHOSPHATASE (BAP) (TANDEM(R)-R OSTASE(TM)) IN MONITORING INDIVIDUAL POSTMENOPAUSAL OSTEOPOROTIC WOMEN UNDERGOING ALENDRONATE (ALN) THERAPY
Authors: MIZRAHI I ARMOUR K EMKEY R MARCUS R SANTORA A KRESS B
Citation: I. Mizrahi et al., CLINICAL UTILITY OF BONE SPECIFIC ALKALINE-PHOSPHATASE (BAP) (TANDEM(R)-R OSTASE(TM)) IN MONITORING INDIVIDUAL POSTMENOPAUSAL OSTEOPOROTIC WOMEN UNDERGOING ALENDRONATE (ALN) THERAPY, Arthritis and rheumatism, 39(9), 1996, pp. 359-359
LOW-DOSE ESTERIFIED ESTROGENS (ESTRATAB) PREVENT POSTMENOPAUSAL BONE LOSS
Authors: EMKEY R WEISS SR FLEISCHMANN R MCILWAIN HH SPERLING M BRENNAN J NOLAN J
Citation: R. Emkey et al., LOW-DOSE ESTERIFIED ESTROGENS (ESTRATAB) PREVENT POSTMENOPAUSAL BONE LOSS, Arthritis and rheumatism, 39(9), 1996, pp. 657-657
3-YEAR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH ORAL ALENDRONATE - EFFECTS ON BONE MASS AND TURNOVER AND SAFETY
Authors: DOWNS R BAKER M BELL N EMKEY R TONINO R TUCCI J WEISS S PEVERLY C KHER U SANTORA A
Citation: R. Downs et al., 3-YEAR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN WITH ORAL ALENDRONATE - EFFECTS ON BONE MASS AND TURNOVER AND SAFETY, Journal of bone and mineral research, 10, 1995, pp. 139-139
3-YEAR TREATMENT WITH ALENDRONATE PREVENTS FRACTURES IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS
Authors: BANKHURST A MCILWAIN H EMKEY R YOOD R ROMANOWICZ A PASSERI M QUAN H SHAPIRO D DAIFOTIS A KARPF D
Citation: A. Bankhurst et al., 3-YEAR TREATMENT WITH ALENDRONATE PREVENTS FRACTURES IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS, Arthritis and rheumatism, 38(9), 1995, pp. 1238-1238
PROGRESSIVENESS AND GENERALIZABILITY OF THE EFFECTS OF ALENDRONATE ONBONE MASS AND SAFETY EXPERIENCE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
Authors: EMKEY R CORREAROTTER R SANTORA A LOMBARDI A DAIFOTIS A
Citation: R. Emkey et al., PROGRESSIVENESS AND GENERALIZABILITY OF THE EFFECTS OF ALENDRONATE ONBONE MASS AND SAFETY EXPERIENCE IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS, Arthritis and rheumatism, 38(9), 1995, pp. 1239-1239
Risultati: 1-16 |